MX347014B - Composición para administración de fármaco biodegradable. - Google Patents

Composición para administración de fármaco biodegradable.

Info

Publication number
MX347014B
MX347014B MX2013005621A MX2013005621A MX347014B MX 347014 B MX347014 B MX 347014B MX 2013005621 A MX2013005621 A MX 2013005621A MX 2013005621 A MX2013005621 A MX 2013005621A MX 347014 B MX347014 B MX 347014B
Authority
MX
Mexico
Prior art keywords
drug delivery
delivery composition
biodegradable drug
vehicle
composition
Prior art date
Application number
MX2013005621A
Other languages
English (en)
Other versions
MX2013005621A (es
Inventor
W Van Osdol William
Il Yum Su
Theeuwes Felix
Sekar Michael
Gibson John
Branham Keith
Su Huey-Ching
Original Assignee
Durect Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Durect Corp filed Critical Durect Corp
Publication of MX2013005621A publication Critical patent/MX2013005621A/es
Publication of MX347014B publication Critical patent/MX347014B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a una composición que comprende; un vehículo que comprende un polímero biodegradable presente en una cantidad desde aproximadamente 5% hasta aproximadamente 40% por peso del vehículo y un solvente hidrófobo presente en una cantidad desde aproximadamente 95% hasta aproximadamente 60% por peso del vehículo; y un complejo disperso en el vehículo, el complejo tienen una solubilidad de menos de 1mg/mL en el vehículo a 25°C, en donde la composición comprende: una proteína, péptido, ácido nucleico o compuesto de peso molecular bajo, el compuesto de peso molecular bajo tiene un peso molecular menor que o igual a aproximadamente 800 Daltons, y un contraión de la proteína, péptido, ácido nucleico o compuesto de peso molecular bajo, en donde la composición tienen una viscosidad de corte cero menor que 1, 200 centipoises a 25°C y en donde la composición no es una emulsión.
MX2013005621A 2010-11-24 2011-11-23 Composición para administración de fármaco biodegradable. MX347014B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41712610P 2010-11-24 2010-11-24
US201161563469P 2011-11-23 2011-11-23
PCT/US2011/062139 WO2012074883A1 (en) 2010-11-24 2011-11-23 Biodegradable drug delivery composition

Publications (2)

Publication Number Publication Date
MX2013005621A MX2013005621A (es) 2013-12-06
MX347014B true MX347014B (es) 2017-04-07

Family

ID=46172227

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013005621A MX347014B (es) 2010-11-24 2011-11-23 Composición para administración de fármaco biodegradable.

Country Status (13)

Country Link
US (5) US20120225033A1 (es)
EP (1) EP2643009A4 (es)
JP (4) JP2013543898A (es)
KR (1) KR20140015266A (es)
CN (2) CN105748402B (es)
AU (3) AU2011336896B2 (es)
BR (1) BR112013011967A2 (es)
CA (1) CA2812102A1 (es)
EA (1) EA026964B1 (es)
MX (1) MX347014B (es)
TW (1) TWI538687B (es)
WO (1) WO2012074883A1 (es)
ZA (1) ZA201302120B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
EP2152315B1 (en) 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
JP5510908B2 (ja) * 2010-02-26 2014-06-04 株式会社ピーアイ技術研究所 半導体装置用ポリイミド樹脂組成物並びにそれを用いた半導体装置中の膜形成方法及び半導体装置
ES2390439B1 (es) 2012-08-03 2013-09-27 Laboratorios Farmacéuticos Rovi, S.A. Composición inyectable
US20140294977A1 (en) * 2011-11-23 2014-10-02 Durect Corporation Radiation-Sterilized Biodegradable Drug Delivery Composition
BR112015022023B1 (pt) * 2013-03-11 2022-12-06 Durect Corporation Composição de liberação controlada injetável compreendendo transportador líquido de alta viscosidade
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
KR101513812B1 (ko) * 2013-11-22 2015-04-20 가천대학교 산학협력단 소수성 약물 전달용 마이크로 구조체의 제조방법
CN105764491A (zh) 2013-12-09 2016-07-13 度瑞公司 药物活性剂复合物、聚合物复合物，以及包括其的组合物和方法
US10786515B2 (en) 2015-08-03 2020-09-29 Tolmar International Limited Liquid polymer delivery system for extended administration of drugs
BR112018077259A2 (pt) 2016-06-30 2019-06-18 Durect Corporation formulações depot
US10682340B2 (en) 2016-06-30 2020-06-16 Durect Corporation Depot formulations
EA201990127A1 (ru) * 2016-12-30 2020-08-18 Дьюрект Корпорейшн Депо-препарат
PE20210047A1 (es) 2018-06-12 2021-01-08 Farm Rovi Lab Sa Composicion inyectable
US20230372317A1 (en) * 2020-10-27 2023-11-23 Pts Consulting, Llc A liquid injectable composition of donepezil

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4853218A (en) * 1987-02-24 1989-08-01 Schering Corporation Zinc-protamine-alpha interferon complex
IT1244647B (it) * 1991-02-05 1994-08-08 Salvatore Mancuso Prodotto farmaceutico per la terapia dei tumori, in particolare di quelli ovarici e del sistema emopoietico, contenente quercitina come principio attivo.
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5968542A (en) * 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
HUP0201626A3 (en) * 1999-06-04 2004-05-28 Alza Corp Mountain View Implantable gel compositions and method of manufacture
US6992065B2 (en) * 2000-04-19 2006-01-31 Genentech, Inc. Sustained release formulations
CA2439120C (en) * 2001-02-23 2011-07-05 Genentech, Inc. Erodible polymers for injection
EP1585959A4 (en) 2002-01-08 2007-11-14 Lilly Co Eli PEPTIDE-1 ANALOGUES OF EXTENSION GLUCAGON TYPE
NZ554885A (en) * 2002-12-31 2009-07-31 Altus Pharmaceuticals Inc Complexes of hgh crystals and protamine polymers
EA009366B1 (ru) 2003-03-19 2007-12-28 Эли Лилли Энд Компани Связанные с полиэтиленгликолем соединения гпп-1
DK1635875T3 (da) * 2003-06-26 2009-01-12 Psivida Inc In-situ-geldannende lægemiddeladministrationssystem
JP2007507516A (ja) * 2003-10-01 2007-03-29 オプティマー・ファーマスーティカルズ・インコーポレイテッド アミノ糖投与による哺乳動物の障害の治療及びアミノ糖の使用
US20050266087A1 (en) * 2004-05-25 2005-12-01 Gunjan Junnarkar Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium
CA2581287C (en) * 2004-09-17 2015-08-25 Durect Corporation Sustained local anesthetic composition containing bupivacaine and saib
RS53890B1 (sr) * 2004-11-10 2015-08-31 Tolmar Therapeutics, Inc. Stabilizovan polimerni sistem za isporuku
ES2391776T3 (es) * 2004-11-22 2012-11-29 Novo Nordisk A/S Formulaciones solubles, estables conteniendo insulina con una sal de protamina
US20060142234A1 (en) * 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
WO2007075534A2 (en) 2005-12-16 2007-07-05 Nektar Therapeutics Al, Corporation Polymer conjugates of glp-1
WO2007139589A1 (en) * 2006-05-26 2007-12-06 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators
JP2010523564A (ja) * 2007-04-03 2010-07-15 トリメリス，インコーポレーテッド 抗ウイルス性ペプチド治療薬の送達のための新規製剤
CA2686137C (en) * 2007-05-18 2021-01-12 Durect Corporation Improved depot formulations
EP2152315B1 (en) * 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System

Also Published As

Publication number Publication date
EA201390612A1 (ru) 2014-08-29
AU2016201819B2 (en) 2017-12-14
AU2011336896A1 (en) 2013-04-11
AU2016201819A1 (en) 2016-04-14
AU2011336896B2 (en) 2015-12-24
JP2017114877A (ja) 2017-06-29
EP2643009A4 (en) 2015-04-01
JP6837457B2 (ja) 2021-03-03
CA2812102A1 (en) 2012-06-07
US20190209654A1 (en) 2019-07-11
JP2013543898A (ja) 2013-12-09
EP2643009A1 (en) 2013-10-02
TW201306869A (zh) 2013-02-16
CN105748402B (zh) 2022-06-03
CN103384528A (zh) 2013-11-06
EA026964B1 (ru) 2017-06-30
ZA201302120B (en) 2014-05-28
BR112013011967A2 (pt) 2016-08-30
WO2012074883A1 (en) 2012-06-07
TWI538687B (zh) 2016-06-21
JP2021073295A (ja) 2021-05-13
AU2018201533A1 (en) 2018-03-22
US20120225033A1 (en) 2012-09-06
US20140193365A1 (en) 2014-07-10
US20170189547A1 (en) 2017-07-06
KR20140015266A (ko) 2014-02-06
CN103384528B (zh) 2016-04-13
MX2013005621A (es) 2013-12-06
CN105748402A (zh) 2016-07-13
US20130259907A1 (en) 2013-10-03
JP2018188457A (ja) 2018-11-29

Similar Documents

Publication Publication Date Title
MX347014B (es) Composición para administración de fármaco biodegradable.
NZ709620A (en) Pharmaceutical formulation comprising an insoluble corticosteroid and a soluble corticosteroid
MX2012000396A (es) Metodos y composiciones para uso en tartamientos celulares.
IN2012DN00570A (es)
EP2498764A4 (en) FRAGMENTED HYDROGEL
PH12013500481A1 (en) Estrogen receptor modulators and uses thereof
PH12012502419A1 (en) Estrogen receptor modulators and uses thereof
PH12014501351A1 (en) Fluorinated estrogen receptor modulators and uses thereof
PH12014501158A1 (en) Composition comprising a shelf-life stability component
PH12015501738A1 (en) Androgen receptor modulators and uses thereof
PH12012500572A1 (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
NZ712350A (en) Abiraterone acetate formulation
EP4414000A3 (en) Compositions of a polyorthoester and an aprotic solvent
EP2488023A4 (en) ANTIMICROBIAL COMPOSITION
MY163055A (en) Polycyclic antagonists of lysophosphatidic acid receptors
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
WO2010017215A3 (en) Biodegradable microspheres and methods of use thereof
MX2013004123A (es) Composiciones antitusigenas que comprenden memantina.
WO2010149727A3 (en) Injectable formulations containing asenapine and method of treatment using same
MX2010003705A (es) Composiciones de fluido de tratamiento de pozos y procedimientos de uso que incluyen una formulacion de percarbonato de liberacion retardada.
MX2015008021A (es) Composiciones y metodos para administracion transdermica de hormonas y otros agentes medicos.
MY160389A (en) Higher loading zinc-containing films
WO2012129429A3 (en) Transdermal compositions comprising an active agent layer and an active agent conversion layer
MY161601A (en) Films and compositions comprising the same
WO2012142328A3 (en) Polymer microsphere compositions for localized delivery of therapeutic agents

Legal Events

Date Code Title Description
FG Grant or registration